It contains no artificial ingredients, colors, or flavors, and is free of common allergens like yeast, wheat, and gluten
The GLP-1 receptor is expressed primarily in pancreatic beta cells, the gastrointestinal tract, and certain areas of the central nervous system, with limited expression in skeletal muscle tissue
UK patients should understand that: Available evidence is largely from Phase 2 studies with relatively short follow-up periods Long-term cardiovascular outcome data are not yet available for either agent Phase 3 trials are ongoing, and results will inform future regulatory submissions to the MHRA UK patients interested in accessing these treatments through clinical trials may wish to consult the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) or ClinicalTrials.gov for current recruitment opportunities
A pre-blended vial is one daily injection at a fixed 5:1:1 ratio convenient, but no dose flexibility
Of note, glycemic control improved with HbA1c reductions reaching 0.8% with survodutide therapy, indicating preserved glycemic benefits despite GCG agonism, likely reflecting the predominant GLP-1 receptor activity ratio
